Teva Pharmaceutical (TEVA) stock gains in premarket after the company posted better than expected Q3 2024 financials and ...

Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price target of $25.00. The company’s shares closed last Friday at $17.11. Prasad covers the ...

5 Highest Paying Countries for Pharmacists A close-up shot of various types of medicines on a table, illustrating the specialty and generic products offered by the pharmaceutical company.

Teva Pharmaceuticals is being fined $503 million (€463 million) by the European Commission for delaying competition posed by rival generic drugmakers, the company’s second major financial ...

Analyst Jason Gerberry of Bank of America Securities reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), boosting ...

Oct. 31 (UPI) --The European Commission fined Teva Pharmaceuticals $503 million for delaying competition posed by rival generic drugmakers, the company's second major financial penalty this month.